Selegiline orally disintegrating tablets for the treatment of Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 5, Issue 6, 2005, Pages 705-712

  Lew, Mark F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dyskinesia; MAO A; MAO B; Metabolites; Monoamine oxidase; Motor fluctuations; Orally disintegrating tablet; Parkinson's disease; Selectivity; Selegiline; Zelapar ; Zydis

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; MOXIFLOXACIN; NORADRENALIN UPTAKE INHIBITOR; OPIATE; PETHIDINE; PHENELZINE; PLACEBO; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE;

AGITATION; ARTHRITIS; CHEST PRESSURE; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; ECG ABNORMALITY; FIRST PASS EFFECT; HALLUCINATION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYASTHENIA; NAUSEA; ORAL IRRITATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; RATING SCALE; REVIEW; SCORING SYSTEM; SIDE EFFECT; STUPOR; TABLET; THORAX PAIN; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPERT TESTIMONY; HUMANS; META-ANALYSIS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PHARMACEUTICAL PREPARATIONS; SELEGILINE;

EID: 27944491594     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.6.705     Document Type: Review

References (35)

1. Marjama-Lyons JM, Koller WC. Parkinsons disease. Update in diagnosis and symptom management. Geriatrics 56(8), 24-35 (2001).
2. Schulz JB, Falkenburger BH. Neuronal pathology in Parkinsons disease. Cell Tissue Res. 318(1), 135-147 (2004).
3. Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinsons disease. Can. Med. Assoc. J. 168(3), 293-301 (2003).
4. Hamani C, Lozano AM. Physiology and pathophysiology of Parkinsons disease. Ann. NY Acad. Sci. 991, 15-21 (2003).
5. Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson s disease: current controversies. Mov. Disord. 19(9), 997-1005 (2004). Levodopa overview, current treatments and unmet needs in Parkinsons disease (PD).
6. Fahn S. Developments in Parkinsons disease therapy. N. Am. Pharmacother. 2, 186-187 (2004).
7. Jankovic J. Levodopa strengths and weaknesses. Neurology 58(4 Suppl. 1), S19-S32 (2002).
8. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinsons disease. A clinical and neuropharmacological study. Brain 107, 487-506 (1984).
9. Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinsons disease: treatment and relation to plasma levodopa profile. Ann. Neurol. 37(1), 120-122 (1995).
10. Obeso JA, Grandas F, Vaamonde J et al. Motor complications associated with chronic levodopa therapy in Parkinsons disease. Neurology 39(11 Suppl. 2), 11-19 (1989).
11. Reardon KA, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinsons disease: a longitudinal study over 6 years. Mov. Disord. 14(4), 605-611 (1999).
12. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinsons disease on the quality of life. Mov. Disord. 20(2), 224-230 (2005).
13. Maurel F, Lilliu H, Le Pen C. Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinsons disease. Rev. Neurol. (Paris) 157(5), 507-514 (2001).
14. Clarke CE. Medical management of Parkinsons disease. J. Neurol. Neurosurg. Psychiatry 72(Suppl. 1), 22-27 (2002).
15. Dewey RB Jr. Management of motor complications in Parkinsons disease. Neurology 62(6 Suppl. 4), S3-S7 (2004).
16. Samii A, Nutt JG, Ransom BR. Parkinsons disease. Lancet 363(9423), 1783-1793 (2004). Good overall disease review.
17. Lang AE, Lozano AM. Parkinsons disease-second of two parts. N. Engl. J. Med. 339(16), 1130-1143 (1998).
18. Silver DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®). Expert Rev. Neurotherapeutics 4(4), 589-599 (2004).
19. Cedarbaum JM, Toy LH, Green-Parsons A. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinsons disease patients with motor response fluctuations. Clin. Neuropharmacol. 14(3), 228-234 (1991).
20. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, and the Zydis Selegiline study group. Zydis selegiline reduces off time in Parkinsons disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. 19(4), 426-432 (2004). First Phase III study of selegiline orally disintegrating tablet (ODT).
21. Rascol O, Brooks DJ, Melamed E et al. for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463), 947-954 (2005).
22. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet. 33(2), 91-102 (1997). Pharmacokinetic and pharmacodynamic studies of conventional oral selegiline.
23. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab. Dispos. 25(6), 657-662 (1997). Summary of selegiline metabolism.
24. Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson's disease. Dysphagia 11(1), 14-22 (1996).
25. Fuh J-L, Lee R-C, Wang S-J et al. Swallowing difficulty in Parkinsons disease. Clin. Neurol. Neurosurg. 99(2), 106-112 (1997).
26. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinsons disease. J. Neurol. Neurosurg. Psychiatry 63(2), 228-234 (1997).
27. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinsons disease. Neurology 39(8), 1109-1111 (1989). Clinical summary of conventional selegiline.
28. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol. 50(4), 375-382 (1998).
29. Clarke A, Brewer F, Johnson ES et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural. Transm. 110(11), 1241-1255 (2003). Pharmacokinetic and pharmacodynamic studies of selegiline ODT.
30. Clarke A, Johnson ES, Mallard N et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J. Neural. Transm. 110(11), 1257-1271 (2003). Clinical trials of selegiline ODT.
31. McCabe BJ. Dietary tyramine and other presser amines in MAOI regimens: a review. J. Am. Diet. Assoc. 86(8), 1059-1064 (1986).
32. Lasseter KC, Morganroth J, Shary W et al. Cardiac safety of a novel MAO-B inhibitor for the treatment of Parkinsons disease. Presented at the 9th International Congress of Parkinsons Disease and Movement Disorders. New Orleans, LA, USA, March 5-8 (2005).
33. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 337(8735), 246 (1991); Comment in
34. Lancet 337(8740), 554 (1991).
35. Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinsons disease. Drug Safety 19(1), 11-22 (1998).